In April 2024, the Substance Abuse & Mental Health Services Administration (SAMHSA) issued a final rule on regulations regarding opioid treatment program (OTP) accreditation, certification, and standards for the treatment of opioid use disorder (OUD). This rule change affects the use of methadone, including clarification on the use of methadone in carceral settings. Under the updated final rules of 42 CFR Part 8, jails and prisons may register as a hospital or clinic. Jails/prisons may stock and dispense methadone to treat OUD and manage acute opioid withdrawal syndrome.
This webinar provided an overview of the updated final rules of 42 CFR Part 8 and how they affect methadone dispensation in carceral settings. Speakers discussed the:
Process for how carceral settings can use the updated SAMHSA rule to increase methadone access;
Drug Enforcement Agency’s (DEA) regulations around dispensing methadone and buprenorphine;
Role of state regulations for accessing MOUD; and
Considerations for carceral settings when establishing a methadone dispensing program.
Speakers:
Kelly Ramsey, MD, MPH, MA, FACP, DFASAM, Internal Medicine and Addiction Medicine Physician, Addiction Medicine and Harm Reduction Consultant
Tisha Wiley, Ph.D., Branch Chief, Associate Director for Justice Systems, National Institute on Drug Abuse (NIDA)
Related Resources from Johns Hopkins University
This webinar is sponsored by the Justice Community Opioid Innovation Network (JCOIN), an initiative funded by the National Institute on Drug Abuse (NIDA). The webinar is also in partnership with the Addiction Policy Forum.